Alx Oncology Holdings (ALXO) Depreciation & Amortization (CF) (2019 - 2026)
Alx Oncology Holdings (ALXO) reported Depreciation & Amortization (CF) of $150000.0 for Q1 2026, down 28.91% on a YoY basis from $211000.0 in Q1 2025, and down 0.66% sequentially from $151000.0 in Q4 2025.
Alx Oncology Holdings (ALXO) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $150000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 28.91% year-over-year to $150000.0; the trailing twelve-month figure through Mar 2026 stood at $645000.0 (down 25.78% YoY), and the FY2025 full-year result was $706000.0, down 19.04% from the prior year.
- Depreciation & Amortization (CF) slipped to $150000.0 in Q1 2026, from $151000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $224000.0 in Q3 2024 to a low of $58000.0 in Q1 2022.
- A 5-year average of $170941.2 and a median of $207000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) soared 1483.33% in 2022 and tumbled 31.7% in 2025, its largest moves.
- Tracing ALXO's Depreciation & Amortization (CF) over 5 years: stood at $105000.0 in 2022, then jumped by 97.14% to $207000.0 in 2023, then climbed by 3.38% to $214000.0 in 2024, then fell by 29.44% to $151000.0 in 2025, then retreated by 0.66% to $150000.0 in 2026.
- Business Quant data shows ALXO's Depreciation & Amortization (CF) at $150000.0 in Q1 2026, $151000.0 in Q4 2025, and $153000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | 150,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 150,000.00 |
| Mar 31, 2026 | 150,000.00 |
| Dec 31, 2025 | 151,000.00 |
| Dec 31, 2025 | 151,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 191,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 220,000.00 |
| Jun 30, 2024 | 220,000.00 |
| Mar 31, 2024 | 214,000.00 |
| Mar 31, 2024 | 214,000.00 |
| Dec 31, 2023 | 207,000.00 |
| Dec 31, 2023 | 207,000.00 |